Back to Search
DAVID ILSON, MD
MD
Internal Medicine Physician
NPI: 1720181696IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
171986(NY)
Education
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
Class of 1986
Research & Publications (20)
Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer.
PMID 17351256·Ann Oncol·2007
3-trial
Cancer of the gastroesophageal junction: Current therapy options.
PMID 16904058·Curr Treat Options Oncol·2006
6-review
Cancer of the gastroesophageal junction: combined modality therapy.
PMID 17030275·Surg Oncol Clin N Am·2006
6-review
New developments in the treatment of esophageal cancer.
PMID 16163169·Clin Adv Hematol Oncol·2004
6-review
Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer.
PMID 15685830·Oncology (Williston Park)·2004
3-trial
Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer.
PMID 12885811·J Clin Oncol·2003
3-trial
Oesophageal cancer: new developments in systemic therapy.
PMID 14585262·Cancer Treat Rev·2003
6-review
Irinotecan, cisplatin, and radiation in esophageal cancer.
PMID 12109799·Oncology (Williston Park)·2002
6-review
Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer.
PMID 18956138·Invest New Drugs·2009
3-trial
Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma.
PMID 19487968·J Thorac Oncol·2009
8-other
Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors.
PMID 19219674·Cancer Invest·2009
3-trial
Chemoradiotherapy in esophageal cancer: toxicity is in the eye of the beholder.
PMID 19247080·J Thorac Oncol·2009
4-observational
Successful treatment of esophageal cancer with airway invasion with induction chemotherapy and concurrent chemoradiotherapy.
PMID 19247092·J Thorac Oncol·2009
5-case
Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer.
PMID 19387328·Ann Surg·2009
8-other
Role of neoadjuvant therapy for esophageal adenocarcinoma.
PMID 19500742·Surg Oncol Clin N Am·2009
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1275 YORK AVE
NEW YORK, NY 10021 - Phone
- (212) 639-2000
Quick Facts
- NPI
- 1720181696
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 40
- Publications
- 20
Are you this provider?
Claim Your Profile